Disc Medicine (IRON) PT Lowered to $71 at Stifel

Disc Medicine (IRON) PT Lowered to $50 at BMO Capital

BMO Capital analyst Evan David Seigerman lowered the price target on Disc Medicine (NASDAQ: IRON) to $50.00 (from $80.00) while maintaining a Outperform rating.

The analyst comments "Post-AURORA we are reducing our target price to $50/share, driven primarily by increased uncertainty as to the true... More

Disc Medicine (IRON) PT Lowered to $43 at Wedbush

Wedbush analyst David Nierengarten lowered the price target on Disc Medicine (NASDAQ: IRON) to $43.00 (from $84.00) while maintaining a Outperform rating.

The analyst comments "IRON reported topline results from AURORA, a placebo-controlled phase 2 study of bitopertin in patients with erythropoietic protoporphyria. The study met its primary endpoint of dose-dependent stat. sig. reduction in protoporphyrin IX (PPIX, the key... More

Raymond James Downgrades Disc Medicine (IRON) to Outperform, 'Mixed Outcome as Key Secondaries Miss Due to Large Placebo Response'

(Updated - April 1, 2024 10:53 AM EDT)

Raymond James analyst Danielle Brill downgraded Disc Medicine (NASDAQ: IRON) from Strong Buy to Outperform with a price target of $40.00 (from $75.00).

The analyst comments "Given high expectations for these data and the uncertainty... More

Disc Medicine (IRON) Reports Topline Results from Phase 2 AURORA Study of Bitopertin

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented topline data from AURORA, a phase 2 study of bitopertin in patients with EPP. Treatment with bitopertin resulted in statistically significant reductions in PPIX, the primary endpoint, and significant improvements in the rate of phototoxic reactions with pain and the Patient Global Impression of Change (PGIC). On the key secondary... More